High-Dose Ablative Radiation Doubles Survival Rates for Patients With Supermassive Bile Duct Tumors

MD Anderson study finds ablative radiation doubles survival for patients with large bile duct tumors, extending median life expectancy to 28.7 months.

By: AXL Media

Published: Apr 3, 2026, 6:57 AM EDT

Source: Information for this report was sourced from University of Texas M. D. Anderson Cancer Center

Breaking the Threshold for Supermassive Tumor Treatment

Medical researchers at The University of Texas MD Anderson Cancer Center have successfully challenged the long-standing belief that very large bile duct tumors are ineligible for radiation therapy. These specific malignancies, known as intrahepatic cholangiocarcinoma, can grow to sizes exceeding 10 centimeters, earning them the classification of "supermassive" tumors. Historically, the medical community avoided using radiation on such large masses due to the extreme risk of damaging the surrounding healthy liver tissue. However, advancements in precision delivery over the last decade have allowed oncologists to target these tumors with ablative doses—levels high enough to completely eradicate cancerous cells—while sparing critical nearby organs such as the stomach and bowels.

Challenging Biological Assumptions in Radiation Oncology

One of the primary barriers to treating supermassive tumors was the prevailing theory that they were biologically distinct and more aggressive than smaller counterparts. Researchers Ethan Ludmir and Eugene Koay conducted extensive molecular and histological analyses to test this assumption, finding no fundamental biological differences between tumors of varying sizes. This discovery led the team to hypothesize that if large tumors are biologically similar to smaller ones, they should respond to radiation with similar efficacy. According to Koay, the study proves that tumor size alone should no longer be a limiting factor in determining whether a patient is a candidate for life-extending radiation therapy.

A Comparative Analysis of Survival and Liver Function

The retrospective study compared outcomes for patients receiving a combination of ablative radiation and chemotherapy against those receiving chemotherapy as a standalone treatment. At a median follow-up of nearly 18 months, the results showed a dramatic disparity in survival outcomes. Patients in the radiation group experienced a median overall survival of 28.7 months, which is more than double the 11.9 months recorded for the chemotherapy-only group. Furthermore, the combination therapy significantly preserved liver function, with tumor-related liver failure occurring in only 12.1% of patients, compared to a staggering 47.1% in those who did not receive the high-dose radiation.